Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 3-armed trial	93 women with severe cyclical mastalgia	Withdrawals from the study due to adverse effects of treatment with danazol with tamoxifen
RCT 3-armed trial	93 women with severe cyclical mastalgia	Weight gain 10/32 (31%) with danazol 200 mg daily over 6 months 0/32 (0%) with tamoxifen 10 mg daily over 6 months	P value not reported
RCT 3-armed trial	93 women with severe cyclical mastalgia	Deepening of the voice 4/32 (13%) with danazol 200 mg daily over 6 months 0/32 (0%) with tamoxifen 10 mg daily over 6 months	P value not reported
RCT 3-armed trial	93 women with severe cyclical mastalgia	Menorrhagia 4/32 (13%) with danazol 200 mg daily over 6 months 2/32 (6%) with tamoxifen 10 mg daily over 6 months	P value not reported
RCT 3-armed trial	93 women with severe cyclical mastalgia	Muscle cramps 3/32 (9%) with danazol 200 mg daily over 6 months 0/32 (0%) with tamoxifen 10 mg daily over 6 months	P value not reported
RCT 3-armed trial	93 women with severe cyclical mastalgia	Hot flushes 4/32 (12%) with danazol 200 mg daily over 6 months 8/32 (25%) with tamoxifen 10 mg daily over 6 months	P value not reported
RCT 3-armed trial	93 women with severe cyclical mastalgia	Vaginal discharge 3/32 (9%) with danazol 200 mg daily over 6 months 5/32 (16%) with tamoxifen 10 mg daily over 6 months	P value not reported